<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01950169</url>
  </required_header>
  <id_info>
    <org_study_id>NutristudienSHFG</org_study_id>
    <nct_id>NCT01950169</nct_id>
  </id_info>
  <brief_title>Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture</brief_title>
  <official_title>Effects of Bisphosphonates and Nutritional Supplementation After a Hip Fracture</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska Institutet</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska Institutet</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that nutritional supplementation together with bisphosphonates have a
      better preserving effect on bone mineral density (BMD) after hip fracture than
      bisphosphonates alone and that nutritional supplementation given postoperatively for 6 months
      preserve lean body mass in elderly hip fracture patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion criteria: Men and women, ≥ 60 years of age with a recent fracture of the femoral
      neck or trochanter, admitted to any of the four University hospitals in Stockholm, Sweden.
      Patients are randomized into three groups by sealed enveloped technique in blocks by 12, thus
      assuring that each center had an equal distribution of patients in the three treatment
      groups. Patients randomly assigned and followed for 12 months. Each center with a doctor in
      charge and a trial nurse. The trial nurse in collaboration with the doctor are responsible of
      the randomization procedure and that blood samples are taken in the morning of the first
      weekday after inclusion at the ward and further that the dual-energy X-ray (DXA) and all
      estimates are done during hospital stay.The pharmacological treatment and nutritional
      supplementation starts as soon as the patients are circulatory stable, able to take food by
      mouth and are able to sit in an upright position one hour after taking the tablets.Patients
      are examined at baseline with a follow up at 6 and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2004</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total hip bone mineral density (BMD) at 6 and 12 months after hip fracture.</measure>
    <time_frame>12 months</time_frame>
    <description>Total hip bone mineral density (BMD) measured by dual X-ray absorptiometry (DXA) at baseline and at 6 and 12 months follow up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total body bone mineral density (BMD), lean and fat mass at 6 and 12 months after hip fracture.</measure>
    <time_frame>12 months</time_frame>
    <description>Total body composition measured by dual X-ray absorptiometry (DXA) at baseline and at 6 and 12 months follow up.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">79</enrollment>
  <condition>Hip Fracture</condition>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>35 mg risedronate orally administered once weekly for 12 months and orally administered Calcium 1000 mg and 800 IU vitamin D3 daily for 12 months. Group B (bisphosphonate group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutritional supplement</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral liquid nutritional supplement (600kcal and 40 gram protein/day) for 6 months after the hip fracture besides Risedronate and calcium and vitamin D3. Group BN (bisphosphonate and nutritional supplemented group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Calcium and vitamin D3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>An oral dose of 1000 mg Calcium and 800 IU vitamin D3 daily for 12 months after hip fracture. Group C (control)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.</description>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_label>Nutritional supplement</arm_group_label>
    <other_name>Bisphosphonate Group (B)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Nutritional supplement</intervention_name>
    <description>The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.</description>
    <arm_group_label>Nutritional supplement</arm_group_label>
    <other_name>Bisphosphonate and nutritional supplemented Group (BN)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Calcium and vitamin D3</intervention_name>
    <description>The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.</description>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_label>Nutritional supplement</arm_group_label>
    <arm_group_label>Calcium and vitamin D3</arm_group_label>
    <other_name>Control Group (C)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 60 years

          -  Recent fracture of the femoral neck or trochanter

          -  Without severe cognitive impairment

          -  Ambulant before fracture

          -  BMI ≤ 28

        Exclusion Criteria:

          -  Abnormal parameters regarding liver i.e. S-Alanine aminotransferase (S-ALAT) and
             S-Aspartate aminotransferase (S-ASAT) ≥ twice as normal

          -  Abnormal parameters regarding kidney i.e. S-Creatinine &gt; 130 µg/L

          -  Primary hyperparathyroidism, osteogenesis imperfecta, Paget´s disease

          -  Myeloma

          -  Lactose intolerance

          -  Dysphagia

          -  Esophagitis

          -  Gastric ulcer

          -  Malignancy

          -  Diabetes with nephropathy or retinopathy

          -  Active iritis or uveitis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margareta Hedström, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maria Sääf, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lena Flodin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institutet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Geriatric Medicine R94, Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 23, 2013</study_first_submitted>
  <study_first_submitted_qc>September 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2013</study_first_posted>
  <last_update_submitted>September 10, 2014</last_update_submitted>
  <last_update_submitted_qc>September 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska Institutet</investigator_affiliation>
    <investigator_full_name>Lena Flodin</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hip fracture</keyword>
  <keyword>Nutritional supplement</keyword>
  <keyword>Bisphosphonates</keyword>
  <keyword>Bone mineral density</keyword>
  <keyword>Body composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Risedronate Sodium</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

